References
- Boeck S, Weigang-Kohler K, Fuchs M, et al (2007). Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol, 18, 745-51.
- Burris HA, III, Moore MJ, Andersen J et al (1997). Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 15, 2403-13.
- Canyilmaz E, Serdar L, Uslu GH, et al (2013). Evaluation of prognostic factors and survival results in pancreatic carcinomas in Turkey. Asian Pac J Cancer Prev, 14, 6573-8. https://doi.org/10.7314/APJCP.2013.14.11.6573
- Chen WQ, Liang D, Zhang SW, et al (2013). Pancreatic cancer incidence and mortality patterns in china, 2009. Asian Pac J Cancer Prev, 14, 7321-4. https://doi.org/10.7314/APJCP.2013.14.12.7321
- Cheung R (2013). Racial and social economic factors impact on the cause specific survival of pancreatic cancer: a SEER survey. Asian Pac J Cancer Prev, 14, 159-63. https://doi.org/10.7314/APJCP.2013.14.1.159
- Choi JG, Seo JH, Oh SC, et al (2012). A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. Cancer Res Treat, 44, 127-32. https://doi.org/10.4143/crt.2012.44.2.127
- Choi M, Saif MW, Kim R (2014). Is there a role for second line therapy in advanced pancreatic cancer? JOP, 15, 106-9.
- Conroy T, Desseigne F, Ychou M, et al (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine, 364, 1817-25 https://doi.org/10.1056/NEJMoa1011923
- Demols A, Peeters M, Polus M, et al (2006). Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer, 94, 481-5. https://doi.org/10.1038/sj.bjc.6602966
- Diaz-Rubio E, Evans TR, Tabemero Jet al (2002). Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, doseescalation study in patients with advanced or metastatic solid tumors. Ann Oncol, 13, 558-65. https://doi.org/10.1093/annonc/mdf065
- Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
- Faivre S, Raymond E, Woynarowski JM, et al (1999). Supraadditive effect of 2',2' difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol, 44, 117-23. https://doi.org/10.1007/s002800050955
- Fernandez E, La Vecchia C, Porta M, et al (1994). Trends in pancreatic cancer mortality in Europe, 1955-1989. Int J Cancer, 57, 786-92 https://doi.org/10.1002/ijc.2910570605
- Fesinmeyer MD, Austin MA, Li CI, et al (2005). Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev, 14, 1766-73. https://doi.org/10.1158/1055-9965.EPI-05-0120
- Glimelius B, Hoffman K, Sjoden PO, et al (1996). Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol, 7, 593-600. https://doi.org/10.1093/oxfordjournals.annonc.a010676
- Herrmann C, Abel U, Stremmel W, et al (2007). Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer. Oncology, 73, 335-9. https://doi.org/10.1159/000134477
- Ignatiadis M, Polyzos A, Stathopoulos GP, et al (2006). A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology, 71, 159-63. https://doi.org/10.1159/000106064
- Inal A, Ciltas A, Yildiz R, et al (2012). Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study. Asian Pac J Cancer Prev, 13, 1841-4. https://doi.org/10.7314/APJCP.2012.13.5.1841
- Kim ST, Choi YJ, Park KH, et al (2012). A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. Clin Oncol (R Coll Radiol), 2, 105-11
- Klapdor R, Fenner C (2000). Irinotecan (Campto R): efficacy as third/fourth line therapy in advanced pancreatic cancer. Anticancer Res, 20, 5209-12.
- Kulke MH, Blaszkowsky LS, Ryan DP, et al (2007). Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol, 25, 4787-92. https://doi.org/10.1200/JCO.2007.11.8521
- Luke C, Price T, Karapetis C, et al (2009). Pancreatic cancer epidemiology and survival in an Australian population. Asian Pac J Cancer Prev, 10, 369-74.
- Mitry E, Ducreux M, Ould-Kaci M, et al (2006). Oxaliplatin combined with 5- FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol, 30, 357-63. https://doi.org/10.1016/S0399-8320(06)73188-8
- Neoptolemos JP, Cunningham D, Friess H, et al (2003). Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol, 14, 675-92 https://doi.org/10.1093/annonc/mdg207
- Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 6, 649-55.
- Pelzer U, Schwaner I, Stieler J, et al (2011). Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer, 47, 1676-81 https://doi.org/10.1016/j.ejca.2011.04.011
- Qureshi A, Hassan U, Azam M. (2011). Morphology, TNM staging and survival with pancreatico-duodenectomy specimens received at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan. Asian Pac J Cancer Prev, 12, 953-6.
- Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet, 40, 85-104. https://doi.org/10.2165/00003088-200140020-00002
- Reni M, Pasetto L, Aprile G, et al (2006). Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer, 94, 785-91. https://doi.org/10.1038/sj.bjc.6603026
- Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30 https://doi.org/10.3322/caac.21166
- Tokh M, Bathini V, Saif MW (2012). First-line treatment of metastatic pancreatic cancer. JOP, 13, 159-62
- Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13,176-81. https://doi.org/10.1016/S1053-4296(03)00031-6
- Tsavaris N, Kosmas C, Skopelitis H, et al (2005). Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs, 23, 369-75. https://doi.org/10.1007/s10637-005-1446-y
- Von Hoff DD, Goodwin AL, Garcia L (1998). Advances in the treatment of patients with pancreatic cancer: Improvement in symptoms and survivial time. Br J Cancer, 78, 9-13
- Xiong HQ, Varadhachary GR, Blais JC, et al (2008). Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as secondline therapy for patients with advanced pancreatic cancer. Cancer, 113, 2046-52 https://doi.org/10.1002/cncr.23810
- Zahir S, Arjmand A, Kargar S, et al (2013). Incidence and trends of malignant and benign pancreatic lesions in Yazd, Iran between 2001 and 2011. Asian Pac J Cancer Prev, 14, 2631-5. https://doi.org/10.7314/APJCP.2013.14.4.2631
Cited by
- An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer? vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5681
- Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6001
- Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1449
- Increased UGT1A3 and UGT1A7 Expression is Associated with Pancreatic Cancer vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1651
- Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation vol.262, pp.3, 2015, https://doi.org/10.1097/SLA.0000000000001441
- Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer vol.66, pp.3, 2015, https://doi.org/10.4166/kjg.2015.66.3.150
- Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy vol.11, pp.2, 2017, https://doi.org/10.5009/gnl16307
- Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies vol.18, pp.7, 2017, https://doi.org/10.3390/ijms18071338